AI drug discovery company XtalPi Holdings Ltd. (2228.HK) announced on Tuesday it expects to report net profit of 100 million yuan ($14 million) or more for 2025, reversing a 1.52 billion yuan loss a year earlier.
The turnaround was driven by several factors, led by a sharp increase in financial asset gains. The company recorded 500 million yuan or more in net gains from financial assets measured at fair value, compared with 25.3 million yuan in gains for 2024. Meanwhile, the company said it expects to report its revenue reached 780 million yuan or more last year, triple the 266 million yuan a year earlier, as losses narrowed at its core businesses.
XtalPi’s main businesses include intelligent robotics and drug discovery solutions. Last June the company signed a pipeline collaboration agreement with U.S. innovative drugmaker DoveTree, with a total order value of about $6 billion.
XtalPi’s shares opened higher but pared gains on Wednesday and closed at HK$9.44 by the midday break, down 1.05%. The stock is up about 56% over the past 52 weeks.
By Lee Shih TaTo subscribe to Bamboo Works weekly free newsletter, click here
